Corporate | 19 September 2003 14:14

Eckert & Ziegler AG english

NEMOD Immuntherapie transfers assets and liabilities to newly founded GmbH&CoKG Corporate-news announcement sent by DGAP. The sender is solely responsible for the contents of this announcement. ——————————————————————————– NEMOD Immuntherapie transfers all assets and liabilities to newly founded NEMOD Biotherapeutics GmbH & Co. KG Berlin, 19.9.03 NEMOD Immuntherapie GmbH, a drug discovery company focusing on oncological indications, today announced that it has transferred all of its assets and liabilities to the newly founded partnership company NEMOD Biotherapeutics GmbH & Co. KG. “The legal transformation into a partnership reestablishes the possi-bility of transferring losses to corporate companies. With this step we open NEMOD for new investors who should help us in executing our clinical development programs starting 2004”, said Dr. Andreas Hey, COO of NEMOD. “With the name change from “Immuntherapie” into “Biotherapeutics” we would like to express that we will not restrict our oncology programs to immunotherapeutic approaches only.” NEMOD Biotherapeutics GmbH & Co. KG (www.nemod.com) is a drug discovery company affiliated with publicly listed Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE 00056597000, German Prime Standard). NEMOD’s development program focuses on oncological indications like gastric, colon, liver, and breast cancer. Lead projects are PankoMab(TM), a therapeutic tumor antibody, and NemodDC(TM), the currently worldwide only cell line, which allows harvesting of human dendritic cells without human donors. Enquiries: NEMOD Biotherapeutics GmbH & Co. KG Dr. Andreas Hey Chief Operating Officer Tel: +49 (0)30 9410 84-282 end of message, (c)DGAP 19.09.2003 ——————————————————————————– WKN: 565970; ISIN: DE0005659700; Index: Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart 191414 Sep 03